Canaccord Genuity Group Cuts Pulmonx (NASDAQ:LUNG) Price Target to $5.00

Pulmonx (NASDAQ:LUNG) had its price target cut by Canaccord Genuity Group from $6.00 to $5.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.38.

Pulmonx Trading Up 25.5%

Pulmonx stock opened at $2.02 on Thursday. Pulmonx has a 12-month low of $1.31 and a 12-month high of $8.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The stock has a market capitalization of $83.33 million, a PE ratio of -1.52 and a beta of 0.07. The firm has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $1.79.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.14. The firm had revenue of $22.60 million for the quarter, compared to analysts’ expectations of $21.73 million. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%. As a group, equities research analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of Pulmonx stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $96,972.59. Following the transaction, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. The trade was a 4.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 98,265 shares of company stock worth $140,519. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Pulmonx

Several institutional investors have recently made changes to their positions in the stock. Susquehanna Portfolio Strategies LLC purchased a new position in Pulmonx during the fourth quarter valued at approximately $133,000. Engineers Gate Manager LP acquired a new position in Pulmonx in the 4th quarter valued at approximately $106,000. ADAR1 Capital Management LLC lifted its position in Pulmonx by 65.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 355,410 shares of the company’s stock worth $785,000 after buying an additional 140,913 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Pulmonx by 144.6% during the 4th quarter. AQR Capital Management LLC now owns 58,919 shares of the company’s stock valued at $130,000 after buying an additional 34,828 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Pulmonx during the 4th quarter valued at $31,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

More Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.